Paper28344808
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
Hege KM and 9 others. J Immunother Cancer, 2017. Cited by 281 papers, by iCite.
Cite this record
ConductScience Library. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Papers, record 28344808. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28344808
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Colorectal Neoplasms | Major topic |
| Glycoproteins | Major topic |
| Receptors, Antigen, T-Cell | Major topic |
| T-Lymphocytes | Major topic |
| Aged | |
| B-Lymphocytes | |
| Carcinoembryonic Antigen | |
| Dose-Response Relationship, Drug | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| Infusions, Intravenous | |
| Interferon-alpha | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIABC010425 | NIH |
Source NIH RePORTER
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10975673 | T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. | Cancer Gene Ther | 2000 | https://conductscience.org/library/papers/10975673 | PubMed |
| 2 | 8195861 | Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. | J Nucl Med | 1994 | https://conductscience.org/library/papers/8195861 | PubMed |
| 3 | 9743337 | Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. | J Immunol | 1998 | https://conductscience.org/library/papers/9743337 | PubMed |
| 4 | 25317870 | Chimeric antigen receptor T cells for sustained remissions in leukemia. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25317870 | PubMed |
| 5 | 12027564 | A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. | Mol Ther | 2002 | https://conductscience.org/library/papers/12027564 | PubMed |
| 6 | 24553386 | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553386 | PubMed |
| 7 | 1705867 | The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. | Cell | 1991 | https://conductscience.org/library/papers/1705867 | PubMed |
| 8 | 10887107 | Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. | Blood | 2000 | https://conductscience.org/library/papers/10887107 | PubMed |
| 9 | 23939024 | Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. | Mol Ther | 2013 | https://conductscience.org/library/papers/23939024 | PubMed |
| 10 | 2297774 | Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. | Cancer Res | 1990 | https://conductscience.org/library/papers/2297774 | PubMed |
| 11 | 19934295 | Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19934295 | PubMed |
| 12 | 20179677 | Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. | Mol Ther | 2010 | https://conductscience.org/library/papers/20179677 | PubMed |
| 13 | 26405231 | Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. | Science | 2015 | https://conductscience.org/library/papers/26405231 | PubMed |
| 14 | 23242161 | Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. | Nat Biotechnol | 2013 | https://conductscience.org/library/papers/23242161 | PubMed |
| 15 | 9049790 | Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. | J Clin Immunol | 1997 | https://conductscience.org/library/papers/9049790 | PubMed |
| 16 | 2810387 | In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. | J Natl Cancer Inst | 1989 | https://conductscience.org/library/papers/2810387 | PubMed |
| 17 | 22437939 | Adoptive immunotherapy for cancer: harnessing the T cell response. | Nat Rev Immunol | 2012 | https://conductscience.org/library/papers/22437939 | PubMed |
| 18 | 21830940 | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21830940 | PubMed |
| 19 | 22047558 | Inducible apoptosis as a safety switch for adoptive cell therapy. | N Engl J Med | 2011 | https://conductscience.org/library/papers/22047558 | PubMed |
| 20 | 2644399 | Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2644399 | PubMed |
Cited by201
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 281 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42780573 | Carbohydrate antigen 72-4 and tumor-associated glycoprotein 72 - tumor marker: Past, present and future. | World J Gastrointest Pathophysiol | 2026 | https://conductscience.org/library/papers/42780573 | PubMed |
| 42761580 | Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42761580 | PubMed |
| 42717494 | Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies. | Biofactors | 2026 | https://conductscience.org/library/papers/42717494 | PubMed |
| 42677388 | From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer. | Chem Rev | 2026 | https://conductscience.org/library/papers/42677388 | PubMed |
| 42416076 | Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strategies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42416076 | PubMed |
| 42397032 | CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance. | Cancer Immunol Res | 2026 | https://conductscience.org/library/papers/42397032 | PubMed |
| 42340347 | Cancer-associated alterations in O-GalNAc glycosylation. | Glycobiology | 2026 | https://conductscience.org/library/papers/42340347 | PubMed |
| 42272961 | Adoptive T-cell therapies in the clinic. | Bioeng Transl Med | 2026 | https://conductscience.org/library/papers/42272961 | PubMed |
| 42039159 | CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42039159 | PubMed |
| 41939861 | Immunomodulation by glycosylation: bridging glycobiology to adaptive immunity and therapeutic innovation. | Front Immunol | 2026 | https://conductscience.org/library/papers/41939861 | PubMed |
| 41928316 | Bridging biomaterials and immunotherapy: hydrogel strategies for next-generation CAR-T cell treatment. | Stem Cell Res Ther | 2026 | https://conductscience.org/library/papers/41928316 | PubMed |
| 41928252 | In vivo CAR-T therapy: from molecular design to precision delivery. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41928252 | PubMed |
| 41639889 | Targeting urological cancers with CAR-T cell therapy: current landscape and future directions. | J Transl Med | 2026 | https://conductscience.org/library/papers/41639889 | PubMed |
| 41518483 | Immunogenicity of Gene and Cell Therapies. | BioDrugs | 2026 | https://conductscience.org/library/papers/41518483 | PubMed |
| 41383027 | Fine-tuning affinity and spacer design enhances T cell potency in DLL3 and BCMA CAR T cells. | MAbs | 2026 | https://conductscience.org/library/papers/41383027 | PubMed |
| 41005308 | Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. | Cell | 2025 | https://conductscience.org/library/papers/41005308 | PubMed |
| 40981188 | Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers. | Med Sci (Basel) | 2025 | https://conductscience.org/library/papers/40981188 | PubMed |
| 40969260 | Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors. | Front Oncol | 2025 | https://conductscience.org/library/papers/40969260 | PubMed |
| 40958736 | Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers. | J Surg Oncol | 2025 | https://conductscience.org/library/papers/40958736 | PubMed |
| 40940743 | Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells. | Cells | 2025 | https://conductscience.org/library/papers/40940743 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28344808
GET https://conductscience.org/api/papers/v1/28344808/references?page=2